Free Trial

Merus (MRUS) Stock Price, News & Analysis

-0.45 (-0.79%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
949,676 shs
Average Volume
792,613 shs
Market Capitalization
$3.33 billion
P/E Ratio
Dividend Yield
Price Target

Merus MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
28.3% Upside
$72.70 Price Target
Short Interest
8.03% of Shares Sold Short
Dividend Strength
News Sentiment
0.46mentions of Merus in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$792,792 Sold Last Quarter
Proj. Earnings Growth
From ($3.12) to ($3.46) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.49 out of 5 stars

Medical Sector

459th out of 913 stocks

Pharmaceutical Preparations Industry

216th out of 429 stocks

MRUS stock logo

About Merus Stock (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock Price History

MRUS Stock News Headlines

Merus (NASDAQ:MRUS) VP Sells $317,340.00 in Stock
Merus (NASDAQ:MRUS) Given Consensus Rating of "Buy" by Analysts
Merus (NASDAQ:MRUS) VP Harry Shuman Sells 6,000 Shares
Merus (NASDAQ:MRUS) Shares Down 2.2% on Analyst Downgrade
Merus (NASDAQ:MRUS) PT Raised to $88.00
See More Headlines
Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$43.95 million
Book Value
$6.17 per share


Free Float
Market Cap
$3.33 billion
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Dr. Sven Ante Lundberg M.D. (Age 61)
    CEO, President & Executive Director
    Comp: $953.06k
  • Mr. Gregory D. Perry (Age 64)
    Chief Financial Officer
    Comp: $63.76k
  • Mr. Peter B. Silverman J.D. (Age 46)
    EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal
    Comp: $601.19k
  • Dr. Hui Liu Ph.D. (Age 57)
    Chief Business Officer, Executive VP & Head of Merus U.S.
    Comp: $597.7k
  • Dr. Andrew Joe M.D. (Age 57)
    Chief Medical Officer & Senior VP
    Comp: $692.74k
  • Dr. Hennie Hoogenboom
    Co-Founder and Scientific Advisor
  • Harry Shuman
    Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D. (Age 59)
    CTO & Executive VP
    Comp: $350.85k
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D.
    Chief Scientific Officer & Senior VP
  • Kathleen Farren
    IR & Corporate Communications Officer

MRUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Merus stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRUS shares.
View MRUS analyst ratings
or view top-rated stocks.

What is Merus' stock price target for 2024?

12 brokers have issued 12 month price objectives for Merus' shares. Their MRUS share price targets range from $45.00 to $93.00. On average, they predict the company's stock price to reach $72.70 in the next year. This suggests a possible upside of 28.3% from the stock's current price.
View analysts price targets for MRUS
or view top-rated stocks among Wall Street analysts.

How have MRUS shares performed in 2024?

Merus' stock was trading at $27.50 at the beginning of the year. Since then, MRUS shares have increased by 106.0% and is now trading at $56.66.
View the best growth stocks for 2024 here

Are investors shorting Merus?

Merus saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 4,710,000 shares, an increase of 35.3% from the May 15th total of 3,480,000 shares. Based on an average trading volume of 933,300 shares, the short-interest ratio is currently 5.0 days.
View Merus' Short Interest

When is Merus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024.
View our MRUS earnings forecast

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) posted its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.24. The biotechnology company had revenue of $7.89 million for the quarter, compared to the consensus estimate of $8.94 million. Merus had a negative net margin of 390.36% and a negative trailing twelve-month return on equity of 44.13%.

What other stocks do shareholders of Merus own?
When did Merus IPO?

Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Who are Merus' major shareholders?

Merus' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lynx1 Capital Management LP (2.57%), Price T Rowe Associates Inc. MD (2.02%), BVF Inc. IL (2.00%), Medicxi Ventures Management Jersey Ltd (1.99%), Janus Henderson Group PLC (0.92%) and Artal Group S.A. (0.78%). Insiders that own company stock include Bvf Partners L P/Il, Harry Shuman, Kruif John De, Lex Bakker, Peter B Silverman and Sven Ante Lundberg.
View institutional ownership trends

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MRUS) was last updated on 6/13/2024 by Staff

From Our Partners